CA Patent

CA2818097C — Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

Assigned to Janssen Sciences Ireland ULC · Expires 2019-07-30 · 7y expired

What this patent protects

The invention provides multilayer tablets that contain rilpivirine hydrochloride, emtricitabine, and tenofivir disoproxil fumarate. The tablets are useful for the treatment of HIV.

USPTO Abstract

The invention provides multilayer tablets that contain rilpivirine hydrochloride, emtricitabine, and tenofivir disoproxil fumarate. The tablets are useful for the treatment of HIV.

Drugs covered by this patent

Patent Metadata

Patent number
CA2818097C
Jurisdiction
CA
Classification
—
Expires
2019-07-30
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Sciences Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.